Cara Therapeutics, Inc.

Cara Therapeutics, Inc. insiders are currently net sellers of CARA stock, showing neutral sentiment over the past 90 days. Total sales of $28.2M outpace purchases of $19.3M, creating a net outflow of $8.9M.

Cara Therapeutics, Inc. has 23 active insiders who have filed SEC Form 4 transactions in the past 90 days. Mark Leschly (Executive) leads with 3 transactions totaling $11.6M. Dean Slagel (Executive) follows with 11 transactions worth $9.9M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. Cara Therapeutics, Inc.'s current score of 41/100 indicates neutral insider sentiment. Scores between 40-60 represent neutral or mixed activity. With $19.3M in purchases and $28.2M in sales, no strong directional conviction is evident.

The most recent insider transaction occurred on Aug 1, 2024, when Posner Christopher (Executive) disposed of 4,149 shares at $0.35 per share for $1.5K. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, CARA insider trading sentiment is currently neutral with an Alignment Score of 41/100. The balanced activity—$19.3M bought vs $28.2M sold—suggests no strong consensus among insiders.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like Cara Therapeutics, Inc.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At CARA, we track all Form 4 filings—currently showing 349 transactions from 23 insiders over 90 days.

A 10b5-1 plan allows Cara Therapeutics, Inc. executives to pre-schedule stock sales when they don't possess material non-public information. At CARA, approximately 12% of recent transactions are 10b5-1 trades. The remaining 88% are discretionary trades, which may carry more informational value.

You can monitor Cara Therapeutics, Inc. (CARA) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 23 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. Cara Therapeutics, Inc.'s current score of 41/100 indicates neutral sentiment with balanced buying and selling activity. This is calculated from $19.3M in purchases versus $28.2M in sales over 90 days, resulting in a net flow of -$8.9M.

SEC Form 4 filings are mandatory reports that Cara Therapeutics, Inc. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At CARA, the most common type is "S" with 30 occurrences. The most recent Form 4 was filed on Aug 1, 2024 by Posner Christopher.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At Cara Therapeutics, Inc., approximately 12% of recent transactions are executed under 10b5-1 plans, while 88% appear to be discretionary trades. The low percentage means most insider activity at CARA represents discretionary decisions with more informational value.